A Phase 3 interventional study of AK102 and Placebo in Hyperlipidemia, sponsored by Akeso. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Akeso · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Hyperlipidemias with a site in China — 30 open to participants now, 37 under way, 7 of them phase 3. Hyperlipidemias · China.
Among the 94 studies in Hyperlipidemias with a site in China, this one is the 44th largest by enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2021, is one of 20 in phase 3, and was the 37th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →30 of the 94 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–79
Jianyin Zhou · Sites in China
Ages 18–65
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 18+
Shanghai 10th People's Hospital · Sites in China
Ages 18–60
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 12 · Phase 3 20 · Phase 4 7
First in 2005; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 155 across the 78 interventional studies, 1,151 across the 16 observational. Of the 44 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 94 have an industry lead sponsor. The 10 most frequent:
Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Akeso has 3 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
10 of the studies in Hyperlipidemias with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07230730Phase 3Beijing Suncadia Pharmaceuticals Co., LtdA Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | 2027-10 |
| NCT05457582Nanjing First Hospital, Nanjing Medical UniversityPCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI | 2026-12-30 |
| NCT07938099Xin LiReal-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors in Patients With ASCVD for Secondary Prevention | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 94 studies in Hyperlipidemias with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the long-term efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.
This is a Phase 3 clinical study to evaluate the long-term efficacy and safety of AK102, a monoclonal antibody, against proprotein convertase subtilisin/kexin type 9 (PCSK9), in subjects with primary hypercholesterolemia and mixed hyperlipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: AK102
Drug: Placebo
Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
Precentage change from baseline of serum LDL-C level
Time frame: At week 52
The incidence and severity of adverse events (AE)
Time frame: Week 0-52
Value and percentage change from baseline of serum TC levels
Time frame: Week 0-52
Value and percentage change from baseline of serum TG levels
Time frame: Week 0-52
Value and percentage change from baseline of serum non HDL-C levels
Time frame: Week 0-52
Value and percentage change from baseline of serum ApoB levels
Time frame: Week 0-52
Value and percentage change from baseline of serum HDL-C levels
Time frame: Week 0-52
Value and percentage change from baseline of serum ApoA-I levels
Time frame: Week 0-52
Value and percentage change from baseline of serum Lp(a) levels
Time frame: Week 0-52
Evaluate the population pharmacokinetic (PK) characteristics of AK102 , such as AK102 concentration
Time frame: Week 0-52
Number and percentage of subjects with positive anti-AK102 antibody (ADA) / neutralizing antibody (NAB) and the time of ADA / nab positivity
Time frame: Week 0-52
Ran from Nov 2021 to primary completion in Jan 2023, 14 months.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is below that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ebronucimab